Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic. Read a statement...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis Video
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
RDMD and MSU Collaborating for IBM Research
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
We are excited to announce a new collaboration with RDMD, a company that aims to jumpstart research for patients...
New Insights on sporadic Inclusion body myositis (sIBM) pathogenesis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Dr. Conrad "Chris" Weihl joins MSU live for a session titled "New Insights on sporadic Inclusion body myositis (sIBM)...
The NT5C1A Antibody Test and its Role in the Diagnosis of Inclusion Body Myositis
![](https://understandingmyositis.org/wp-content/uploads/avatars/18/5c26225d19e4a-bpthumb.png)
Learn more about the NT5CIA antibody and its association with inclusion body myositis from Dr. Kevin Dooley, a retired...